Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Submacular Vascularized Pigment Epithelial Detachment
NCT01722656Phase 4Completed
- Sponsor
- Southern California Desert Retina Consultants
- Start
- Nov 2012
- Primary completion
- Sep 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in exudative macular degeneration, sponsored by Southern California Desert Retina Consultants. Started Nov 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01722656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01722656.